Whalesbook
Market Rebound Masks Underlying Weakness
Wednesday's market rebound, driven by easing geopolitical fears and lower crude oil prices, provided some relief for investors. However, beneath the surface, the situation is more complex. While Indian stocks climbed, the Indian Rupee hit record lows, and foreign investors continued to withdraw substantial funds. This contrast between market gains and underlying economic challenges suggests investors should focus on company resilience rather than broad optimism.
Drivers of the Day's Rally
Indian markets saw a broad rally on Wednesday, with the Nifty closing up 1.72% at 23,306.45. The gains were driven by crude oil falling below $100 and hopes of US-Iran talks easing global tensions. Realty, metals, and financials led sector gains, while mid and small-cap stocks rose about 2.5%, indicating a temporary surge in risk appetite. Individual stocks like BSE gained 3.00% to ₹2,890.20, Delhivery rose 2.73% to ₹430.35, and Glenmark Pharmaceuticals was up around 3.47% to ₹2,168.50. Despite this uplift, the India VIX, a measure of market volatility, stayed high, indicating investors remain cautious.
Economic Pressures Mount: Rupee and Outflows
Significant economic pressures are testing the market, especially the sharp decline of the Indian Rupee. The currency dropped below 93, reaching a record low of Rs. 93.81 against the US dollar on March 20, 2026, and then 94.2900 by March 26, 2026. This weakening is linked to high crude oil prices, West Asian geopolitical risks, and large foreign investor outflows. In March 2026 alone, Foreign Institutional Investors (FIIs) withdrew a record ₹1.1 lakh crore from Indian stocks, with heavy selling in financial services and auto sectors. Reports indicate the Reserve Bank of India intervened by selling over $15 billion in March to support the rupee, drawing down foreign exchange reserves.
Valuation Concerns Amidst Macro Risks
Valuations for some companies mentioned appear high given the current economic climate. Delhivery, a logistics company, has a Price-to-Earnings (P/E) ratio between 171 and over 233. This is very high and suggests ambitious growth expectations that might be hard to meet amidst current economic uncertainty. Glenmark Pharmaceuticals' P/E ratio of about 57.5x is significantly higher than its peers (average 24.9x) and its own past averages, raising questions about its current valuation. BSE, a leading exchange operator with strong financials like a 36.0% ROE, trades at a P/E of around 55.90, well above the Sensex index P/E of 20.7, indicating growth is already factored into its price. The pharma sector faces challenges like US market price drops and regulatory reviews, affecting Glenmark. The logistics sector, though growing, has intense competition and high capital needs, making high P/E multiples for companies like Delhivery a concern.
Analyst Outlook and Sector Projections
Analysts suggest a cautious approach, recommending selective investments over broad bets. Ajit Mishra, Senior Vice President – Research at Religare Broking Ltd., advises favoring stocks that consistently outperform. For the Nifty, immediate support is expected between 22,600 and 23,000, with potential gains towards 23,600–23,800. Goldman Sachs forecasts the Indian Rupee could fall to Rs. 95 per USD in the next 12 months, depending on crude oil prices and FII flows. The pharmaceutical sector is projected to grow at an 8.1% CAGR from 2026 to 2033, and the logistics sector by 10.7% CAGR by 2026.